Blogs
Chimeric Antigen Receptor (CAR) therapies represent a maturing class of therapeutics with both significant clinical impact and significant analytical complexity. Unlike small molecules or traditional biologics, CAR‑T cells are living drugs with dynamic behavior that introduces a level of complexity that cannot be measured by just a single…
Podcasts
Episode 31 of The Conversational Flow Podcast dives deep into some of the most exciting developments currently shaping the future of cell therapy, flow cytometry, and AI-driven drug development. Our hosts, Brian and Adam, discuss major advances in allogeneic and in vivo CAR-T therapies, including how new manufacturing platforms…
June 6
- June 10
KCAS Bio will be exhibiting at the CYTO 2026, the 39th annual Congress of the International Society for the Advancement of Cytometry. CYTO 2026, hosted by the International Society for the Advancement of Cytometry (ISAC), is the premier annual congress dedicated to the science and engineering of cytometry. This…
Blogs
CyTOF and spectral flow cytometry are widely used technologies for high-dimensional single cell profiling of immune cells. Both technologies enable multiparameter single-cell analysis, but they differ significantly in how data are generated, how quickly studies can be executed, and how flexible an assay can be tailored for a…
News
In modern bioanalytical research, data quality remains the defining metric of success. At the same time, study complexity continues to increase. KCAS Bio is advancing its global flow cytometry services with a focused strategy that integrates AI-enabled efficiencies, harmonized workflows, and high-parameter technologies. The goal…
Podcasts
The main discussion of this 30th episode of “The Conversational Flow” centers on automation in flow cytometry, focusing on a recent paper comparing three major sample preparation systems and their impact on efficiency, standardization, and error reduction. Our hosts, Adam and Brian, explore how automation can significantly reduce hands-on…
Blogs
At KCAS Bio, we supported a therapeutic monoclonal antibody for advanced solid tumors from non-human primate (NHP) toxicology through first-in-human (FIH) dose escalation into phase 2 expansion. This project combined receptor occupancy assays (ROA) by flow cytometry for cell-surface binding on monocytes, immunophenotyping (IPT) for activation markers,…
Blogs
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or…
Podcasts
In episode #29 of “The Conversational Flow” podcast, our hosts, Brian and Adam, are joined by guests from Accelerating Cancer Immunotherapy Research (ACIR), a nonprofit dedicated to sharing important advances in cancer immunotherapy with the scientific community and the public. Ute Burkhardt discusses her background in cancer vaccines and…
Blogs
Reliable immune profiling across global studies depends on methods that perform consistently, regardless of where they are run. We address this question in the white paper entitled “Cross-Site Validation of a 15-Color Spectral Cytometry Panel for Leukocyte Profiling,” documenting a global collaboration between KCAS Bio and its strategic…
Posters & Papers
Discover in this white paper a global collaboration between KCAS Bio and its strategic partner, Crux Biolabs, to harmonize and validate a standardized 15-color spectral flow cytometry panel for pan-leukocyte profiling across multiple sites. If you have any questions about these services or any others…
Podcasts
In episode 28 of “The Conversational Flow”, our hosts, Adam and Brian, discuss why standardization is essential for credible flow cytometry data at scale. They walk through the biggest sources of variability – reagents and lots, sample handling and shipping time, anticoagulants and processing choices (whole blood vs. PBMCs,…